Target
Aromatase inhibitors
6 abstracts
Abstract
Assessment of endocrine therapy adherence in a nurse-led cancer survivorship clinic: Results from the Linking You to Support and Advice (LYSA) trial.Org: Cancer Research @UCC, College of Medicine and Health, University College Cork, CUH/UCC Cancer Centre, Cork University Hospital Group, CUH/UCC Cancer Centre & Cancer Trials Ireland,
Abstract
A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer (BC) and oncotype recurrence score (RS) ≤25 (OFSET): NRG-BR009.Org: Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, MedStar Health, University of Pittsburgh School of Public Health, University of Pittsburgh Medical Center (UPMC),
Abstract
First-in-human phase 1/2a study of the first-in-class, next-generation CDK4-selective inhibitor PF-07220060 + endocrine therapy (ET): Updated safety data in patients with HR+/HER2− mBC.Org: Centro Oncologico International,
Abstract
Cost-effectiveness of adjuvant abemaciclib and ribociclib in high-risk, hormone receptor–positive, early breast cancer in India.Org: Department of Medical Oncology, BRA-IRCH,
Abstract
A window-of-opportunity (WOO) trial of giredestrant +/- LHRHa vs anastrozole+LHRHa in premenopausal women with ER+/HER2- early breast cancer (EBC; IBCSG 67-22; PREcoopERA).Org: European Institute of Oncology, Milan, Italy, Dana-Farber Cancer Institute and International Breast Cancer Study Group Statistical Center, Boston, MA, Peter MacCallum Cancer Centre, Melbourne, Australia, European Institute of Oncology IRCCS, and University of Milan, Milano, Italy, Breast Unit, Helios University Clinic, University Witten-Herdecke, Wuppertal, Germany,
Abstract
Evolution of breast cancer management in the Dominican Republic in the 21st century.Org: FUNDEONCAP, IOHP, Dominican Society of Oncology,